Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM, Falk KN, Mehta S, Hall EF, Menhaji K, Sappenfield EC, Brown OE, Ringel NE, Chang OH, Tellechea LM, Barnes HC, Jeney SES, Bennett AT, Cardenas-Trowers OO. Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options. Obstetrics And Gynecology 2021, 137: 454-460. PMID: 33543891, DOI: 10.1097/aog.0000000000004279.Commentaries, Editorials and LettersConceptsOveractive bladderΒ3-adrenoceptor agonistHealth care inequalitiesOral medicationsFavorable side effect profileTreatment of OABAlternative oral treatmentSecond-line therapySide effect profileCare inequalitiesIdiopathic overactive bladderCognitive side effectsHealth care professionalsQuality of lifeProcedural therapiesOral treatmentEffect profileOAB medicationsTreatment algorithmTreatment optionsChronic conditionsCare professionalsSide effectsMedicationsBetter care